Nuclear factor-kappaB polypeptide inhibitor and application thereof

Abstract

The invention relates to the field of medicines and in particular relates to a polypeptide which contains an inhibition nuclear factor-kappaB and can be used for preventing and treating rheumatoid arthritis. A sequence of the polypeptide is KPARGDGFPAAM and is brand-new. The polypeptide provided by the invention has the beneficial effects that the polypeptide can be used for treating the rheumatoid arthritis and has potential new medicine development value.

Description

Technical field: [0001] The invention relates to the field of medicine, in particular to a nuclear factor-κB polypeptide inhibitor used for preventing and treating or preventing rheumatoid arthritis. Background technique: [0002] Rheumatoid arthritis (rheumatoid arthritis, RA) is the most common clinical inflammatory joint disease and one of the main disabling factors. It is about 0.5%-1.0% in the world, and the incidence of RA is about 0.4% in our country. RA can occur at any age, and the incidence rate increases with age. The high-incidence age of women is 45-55 years old, and gender is closely related to the incidence of RA, with a male-to-female ratio of about 1:3. RA is a chronic systemic inflammatory disease of unknown etiology, with chronic, symmetrical, polysynovial arthritis and extra-articular lesions as the main clinical manifestations, and belongs to autoimmune inflammatory disease. Patients often have hand or wrist pain and swelling (especially the swelling ...

AI Technical Summary

Problems solved by technology

2. Steroid hormones. Hormones are very good analgesic and anti-inflammatory drugs, but long-term use alone cannot improve the condition, but bring many side effects. Steroids can be used as a transitional second-line slow-acting drug before it takes effect, but the dosage should be limited. small, not too long

However, there are no well-developed nuclear factor-κB peptide inhibitors available for the treatment of RA

Images